P. Bandopadhyay, R. D'Rozario, A. Lahiri, J. Sarif, Y. Ray, S. Paul, R. Roy, R. Maiti, K. Chaudhuri, S. Bagchi, A. Maiti, M. Parwez, B. Sharma Sarkar, D. Roy, R. Chakraborty, J. Vasudevan, S. Sharma, D. Biswas, C. Maiti, B. Saha, P. Bhattacharya, R. Pandey, S. Chatterjee, S. Paul, D. Ganguly
medRxiv, 2020
In a randomized control trial on convalescent plasma therapy (CPT) in severe COVID-19, we characterized the nature, in terms of abundance of forty eight cytokines, and dimensions, in terms of their interrelationships, of the hyper-immune activation-associated cytokine storm in patients suffering from acute respiratory distress syndrome. We found plasma MCP3 level to be a key correlate for mitigation of hypoxia, irrespective of therapeutic regimen. We also identified an anti-inflammatory role of CPT independent of its neutralizing antibody content, and a linear regression analysis revealed that neutralizing antibodies as well as the anti-inflammatory effect of CPT both contribute to marked immediate reductions in hypoxia, as compared to patients on standard therapy.
Cited by 7 publications.
Field of study: Medicine